Study KBP-2020-CPHG Documenting New Cases of Primary Lung Cancer (PLC) Diagnosed in Respiratory Medicine Departments and Lung Cancer Units at General Hospitals From January 1st to December 31st 2020

Study Overview
=================
Brief Summary
-----------------
Twenty years after KBP-2000-CPHG study and ten years after KBP-2010-CPHG study, the CPHG proposes to conduct a new epidemiological study on primary PLC in order to evaluate and analyze the changes that have occurred over the last decade. Primary endpoint: Estimate 1-year- and 5-year-mortality rates in patients with PLC. Secondary endpoints: Describe PLC patient population managed by pulmonologists at French General Hospitals in 2020 Describe PLC diagnostic and therapeutic management by pulmonologists at French General Hospitals in 2020 and compare them to KBP-2000-CPHG and KBP-2010-CPHG studies Estimate prognostic factors Compare patient and tumor characteristics to those observed for KBP-2010-CPHG and KBP-2000-CPHG studies Compare observed survival rates to those reported for KBP-2000-CPHG and KBP-2010-CPHG studies

Official Title
-----------------
Study KBP-2020-CPHG Documenting New Cases of Primary Lung Cancer (PLC) Diagnosed in Respiratory Medicine Departments and Lung Cancer Units at General Hospitals From January 1st to December 31st 2020

Conditions
-----------------
Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years Primary Lung Cancer histologically (or cytologically or presence of a mutation on liquid biopsy with compatible imaging) proven between January 1st and December 31st, 2020* Follow-up by a lung specialist at a General Hospital Oral informed consent * date of collected sample Exclusion Criteria: Age < 18 years Secondary lung cancer Recurrence of same histological type PLC- left to the investigator discretion according to the clinic and the imagery Previous enrolment in the study Freedom deprived patient following a legal or administrative decision Patient unable to give his(her) consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Estimate 1-year mortality rates in patients with PLC. | Global survival at 1 year | 1 year | 
| Estimate 5-year mortality rates in patients with PLC. | Global survival at 5 years | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Describe PLC patient population managed by pulmonologists at French General Hospitals in 2020 | - Patient data: age, gender, birth location, height, weight, comorbidity score, smoking status, cannabis uptake, Performance Status, and death | 1 year | 
| Describe PLC diagnostic and therapeutic management by pulmonologists at French General Hospitals in 2020 and compare them to KBP-2000-CPHG and KBP-2010-CPHG studies | - Disease data: diagnostic method, anatomopathological classification, PDL-1 status, molecular biology test, tumor mutation burden, TNM classification, and stage (8th edition) | 1 year |